Business Operations:

Sector: Healthcare
Industry: Medical Distribution

Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; distributes plasma and other blood products, vaccines, and other specialty pharmaceutical products; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; sales force services to manufacturers; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.

Revenue projections:

With Cencora, Inc.'s revenues forecasted to be lower than last year's, investors are expected to be cautious. A decline in revenue typically harms the company's bottom line, reducing profitability and making investors less confident about the company's ability to sustain its financial health.

Financial Ratios:

currentRatio	0.935000
forwardPE	15.588029
debtToEquity	446.516000
earningsGrowth	0.119000
revenueGrowth	0.051000
grossMargins	0.039610
operatingMargins	0.014150
trailingEps	13.480000
forwardEps	19.826110

COR's Forward PE is within a good range, showing that the stock price compares well to its earnings. This suggests it isn't overpriced and leaves room for growth, making the stock appealing to investors looking for value and growth opportunities.
COR's high debt-to-equity ratio indicates the company is using significant leverage, relying more on debt to finance its operations. This can lead to higher risk, especially if profitability falters or economic conditions worsen.
Cencora, Inc.'s forward EPS exceeding its trailing EPS reflects expectations of increased profitability for the current year. This suggests that the company is projected to achieve higher earnings than in the previous financial year, signaling positive growth and improved financial health.

Price projections:

The current price of Cencora, Inc., relative to its projections, shows no clear risks or opportunities. This neutral assessment may encourage investors to take a cautious approach, awaiting further developments before making substantial changes.

Insider Transactions:

Cencora, Inc. experienced 16 selling transactions, with market price of 327.2743740081787.3 transactions to buy COR shares were recorded, with market price at 270.27332560221356.The trend of more sells than buys around Cencora, Inc.'s current price levels suggests possible weakness. If this pattern continues, it could lead to additional price declines, as selling pressure might increase, signaling investor concerns.

Recommendation changes over time:

Analysts have shown a buy bias for Cencora, Inc., marking it as a favorable investment option. This could inspire investors to see Cencora, Inc. as a strong place to park their money, given the positive outlook and growth potential associated with the stock in recent evaluations.